Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd) in Patients with Hormone Receptor (HR) Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.

J Clin Pharmacol · 2026 · PMC13084299 · PMID 41987715

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Exposure‐efficacy analysis suggested a clear trend of improved OS with higher PK exposure.

also in 19,460 other papers

a positive trendno p-value reported

Progression‐free survival (PFS) showed a positive trend with higher exposure, though baseline tumor size emerged as a more significant predictor in multivariable analyses.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.